Related content

Pharmacogenomics of IFN-&bgr;β in multiple sclerosis: towards a personalized medicine approach

By Vosslamber Saskia   van Baarsen Lisa GM   Verweij Cornelis L  

Pharmacogenomics, Vol. 10, Iss. 1, 2009-01 ,pp. : 97-108

Future Medicine

Access to resources Recommend Favorite

Allelic combinations of immune-response genes as possible composite markers of IFN-&bgr; efficacy in multiple sclerosis patients

By Kulakova Olga G   Tsareva Ekaterina Yu   Boyko Alexey N   Shchur Sergey G   Gusev Evgeny I   Lvovs Dmitrijs   Favorov Alexander V   Vandenbroeck Koen   Favorova Olga O  

Pharmacogenomics, Vol. 13, Iss. 15, 2012-11 ,pp. : 1689-1700

Future Medicine

Access to resources Recommend Favorite

Pharmacogenomics of the response to IFN-&bgr;β in multiple sclerosis: ramifications from the first genome-wide screen

By Vandenbroeck Koen   Matute Carlos  

Pharmacogenomics, Vol. 9, Iss. 5, 2008-05 ,pp. : 639-645

Future Medicine

Access to resources Recommend Favorite

Genetic polymorphisms, their allele combinations and IFN-&bgr;β treatment response in Irish multiple sclerosis patients

By O’’Doherty Catherine   Favorov Alexander   Heggarty Shirley   Graham Colin   Favorova Olga   Ochs Michael   Hawkins Stanley   Hutchinson Michael   O’’Rourke Killian   Vandenbroeck Koen  

Pharmacogenomics, Vol. 10, Iss. 7, 2009-07 ,pp. : 1177-1186

Future Medicine

Access to resources Recommend Favorite

United Europeans for development of pharmacogenomics in multiple sclerosis network

By Vandenbroeck Koen   Comabella Manuel   Tolosa Eva   Goertsches Robert   Brassat David   Hintzen Rogier   Infante-Duarte Carmen   Favorov Alexander   Escorza Sergio   Palacios Ricardo   Oksenberg Jorge R   Villoslada Pablo  

Pharmacogenomics, Vol. 10, Iss. 5, 2009-05 ,pp. : 885-894

Future Medicine

Access to resources Recommend Favorite